Corroborating this, an article [37] stated that the studies conducted so far in tumor and normal tissue samples depend on the use of commercially and non-commercially available antibodies recognizing both ENO1 and MBP-1, which has made it difficult to clearly assess the relative expression of the two proteins by immunohistochemistry. Here, ENO1 is linked to neoplasm.